c-erbB-2 expression in benign and malignant breast disease - Wikidata - wikimedia - TriplyDB

c-erbB-2 expression in benign and malignant breast disease

c-erbB-2 expression in benign and malignant breast disease

http://www.wikidata.org/entity/Q36466645

about

Molecular genetics of solid tumours: translating research into clinical practice. What we could do now: breast cancer The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells.Ligand-directed retroviral targeting of human breast cancer cells.The significance of immunohistochemistry in the diagnosis and therapy of neoplasms.C-Erb-b2 oncogene expression in intraductal proliferative lesions of the breast.The subcellular localization of the neu protein in human normal and neoplastic cells.Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast.Molecular analysis of premalignant and carcinoma in situ lesions of the human breast.Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.Prognostic significance of c-erbB-2 expression in node negative breast cancer The long term prognostic significance of c-erbB-2 in primary breast cancer c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.c-erbB-2 oncoprotein expression in primary and advanced breast cancer The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival.An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer.Epidermal growth factor receptor, but not c-erbB-2, activation prevents lactogenic hormone induction of the beta-casein gene in mouse mammary epithelial cells.Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.c-erbB-2 expression in different histological types of invasive breast carcinoma.Apocrine adenosis: a precursor of aggressive breast cancer?c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer.Genetic alterations in primary breast cancer.The PR status of the originating cell of ER/PR-negative mouse mammary tumors.The type I growth factor receptors in human breast cancer.Prognostic factors in breast cancer: use of cytologic preparations.Expression of the ERBB2 protein in benign and malignant salivary gland tumors.Rat monoclonal antibodies to the external domain of the product of the C-erbB-2 proto-oncogene.c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.c-erbB-2 oncogene as a prognostic marker in breast cancer.C-erbB2 mRNA expression in human breast tumours: comparison with c-erbB2 DNA amplification and correlation with prognosis.ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients.Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ.Keratinocyte induced chemotaxis in the pathogenesis of Paget's disease of the breast.The neu-oncogene protein as a predictive factor for haematogenous metastases in breast cancer patients.

P2860

Q24535378-52774A50-A52C-4E78-9A5D-083377F7A8F8 Q24802857-14312485-DAD5-4F3D-9033-148BCDF148B4 Q30472067-4CBA6EEC-073A-496B-A4A6-74E034B2505C Q33868131-3B17982A-3F59-4C10-80D6-1C6F7B06EDA6 Q34602545-761BC3B2-F931-48F6-A3CC-B0A46FCE2B68 Q35184326-5E1C6E66-435B-48FE-A9D6-F4BD5FE2D804 Q35573517-FDA55073-4A9A-43F9-A298-50B51F4DAF9F Q35765309-0C89E451-7F33-4FAA-8295-D86D5071A509 Q35782037-49976C57-8C5C-4C57-92AF-270AD79CEB96 Q35787289-75DF085B-B3D6-487A-82E5-71FE6A52E925 Q35846896-D9550D85-A5C7-430E-9E33-952F293E3FF3 Q35976044-106666F6-FDE9-4E59-AB58-4D7653B40F6D Q35983210-F71C04EA-2D7A-46EE-A04E-3B7D39EFADE6 Q35983237-BF66ECAF-11FE-40BA-B704-C1DAD094CD80 Q35983286-58DE6364-CAEC-4527-99C5-FC8EB2383379 Q35983317-9428E607-6A70-4323-9518-58EB46C7DCC7 Q36136580-D93B2E16-AC82-4401-B80E-4C7E390B3309 Q36421775-8B8DBDA3-7E3F-47BE-BB6A-403948F0543F Q36467701-91A5F26C-43E5-45D0-8CA2-7963A88657F5 Q36719220-137EDC2E-69EA-42CD-9076-F6C850F8BB8E Q37082263-3EEED365-8500-4D75-9FDB-4579C86EC7E4 Q37119722-4D55FB68-A6FD-4983-A1E2-A7498DFA94B6 Q37143922-EAACC836-231A-4EC6-906C-8B5A26DD1DB5 Q37265571-9553377B-4FB8-4231-9390-3D69A6AA2461 Q38478519-B328E877-CABA-4A16-ADDC-6C9E3C14B731 Q38671576-B237B4D8-CE03-42BA-88FA-C41D67248B9D Q40239612-3D792AF7-00AC-46F8-A77B-257483204B4B Q40623955-BB279E5F-382E-49D2-BFB9-06C3767836B4 Q41134041-D56A5A21-C601-448A-8FD0-A1D2836F40D0 Q41694300-9124EF66-062D-47E7-AE83-D23B920683EF Q41744043-B3440FEA-00B9-4DFB-9C39-ACA38C227346 Q41885197-C63B8C94-E549-441A-A667-E7AAB6BEF687 Q42383432-D2E51D8E-3895-402A-B242-4A3D1BE573A3 Q42384421-B9979243-C11B-4F61-A0E8-D36FDB1A4372 Q42983446-CCA1E4D5-B60F-4818-8FAF-6D86A9A642D9 Q43954893-79889970-99A2-4E29-A69C-138B806376B9 Q44062327-D7EB7C28-AF99-4BE9-ADAA-3545963F810B Q46891380-725B15C4-6D76-415D-B088-6EF0D80B7F04 Q49111207-2B322110-C2E2-42A6-8903-7B152E19105C Q49127827-54A4F2DD-4B67-4DA5-A029-E25EDF0FB73B

P2860

c-erbB-2 expression in benign and malignant breast disease

http://www.wikidata.org/entity/Q36466645

description

1988 nî lūn-bûn

@nan

1988年の論文

@ja

1988年学术文章

@wuu

1988年学术文章

@zh-cn

1988年学术文章

@zh-hans

1988年学术文章

@zh-my

1988年学术文章

@zh-sg

1988年學術文章

@yue

1988年學術文章

@zh

1988年學術文章

@zh-hant

name

c-erbB-2 expression in benign and malignant breast disease

@ast

c-erbB-2 expression in benign and malignant breast disease

@en

type

label

c-erbB-2 expression in benign and malignant breast disease

@ast

c-erbB-2 expression in benign and malignant breast disease

@en

prefLabel

c-erbB-2 expression in benign and malignant breast disease

@ast

c-erbB-2 expression in benign and malignant breast disease

@en

P1433

Q36466645-48185C06-5A34-4C0A-A8E4-78996FF74BE8

P1476

Q36466645-58A6A164-8D88-4B1B-ADA6-62C53CEEB571

P2093

Q36466645-290DD962-BB37-4B35-8E05-C892517053A6

Q36466645-30A2E734-DB37-48E8-849B-B847BD81C980

Q36466645-47AB791B-3877-43BE-A2F4-8C6E85D7B083

Q36466645-6B5EAB41-8126-48DF-BA34-3176BB9FD5AA

Q36466645-755E9F24-ACAE-4E2D-B723-253E69982B5A

Q36466645-A55727E6-E262-4CFD-98B6-A62CAD9E9140

Q36466645-B7ADFA28-F0C2-44EA-95E8-241A0B66F817

Q36466645-CBD6374A-86C2-4C68-B53A-7E5044A8F8C3

Q36466645-D987A93C-AB55-43BE-82B7-E6A1ACA15D7B

P2860

Q36466645-010524DB-85DB-44C5-873D-6AF48613363E

Q36466645-0489379B-C077-4CB7-A09D-70DFD01118B6

Q36466645-136F56B6-3750-4676-931D-2105C56375DF

Q36466645-28278F04-4E73-4F27-8F4B-88E6EE5B7F55

Q36466645-2EB6206F-FC90-4F33-993B-17B92EF08683

Q36466645-50052229-AA65-4593-92C1-33B217818B84

Q36466645-5531D07F-4F0D-4983-83BE-5663068E94B4

Q36466645-5E3E4CF5-0E97-4233-A345-A1F973E8254B

Q36466645-6C8EEDE9-31CF-4B6E-AD2C-C03FE4768E57

Q36466645-80D6DE7C-3C22-4732-8AA1-23FEDB21A11C

P2888

Q36466645-D565D32C-9D0C-4575-9C4D-159BA914E82E

P304

Q36466645-2FC3B007-97BA-4633-8AF8-1A2A74D511FC

P31

Q36466645-63558D53-5B3F-49AB-A15F-6FAAEBD999C2

P356

Q36466645-2DF0CE05-C181-4D38-A2AF-7FDA588E0928

P407

Q36466645-93053E28-8C3D-48CA-A881-65343A4EFD0B

P433

Q36466645-3A372FA7-EC5F-486A-8892-5890AB5A0807

P478

Q36466645-40DEBB2A-0458-498E-8BAF-28A091CD6C74

P577

Q36466645-9649AF54-D480-4674-9136-6292E386204D

P5875

Q36466645-20478B9F-B5C5-4EA5-8133-C3B70A21B0C8

P698

Q36466645-A435B09F-302C-477B-B1BC-D80352D86775

P932

Q36466645-5D0A3AEF-7508-4273-AC5A-9252E694D5BA

P356

P1433

British Journal of Cancer

P1476

c-erbB-2 expression in benign and malignant breast disease

@en

P2093

Ashley S

http://www.w3.org/2001/XMLSchema#string

Elliott C

http://www.w3.org/2001/XMLSchema#string

Gibbs NM

http://www.w3.org/2001/XMLSchema#string

Gullick WJ

http://www.w3.org/2001/XMLSchema#string

Gusterson BA

http://www.w3.org/2001/XMLSchema#string

Harrison S

http://www.w3.org/2001/XMLSchema#string

Machin LG

http://www.w3.org/2001/XMLSchema#string

Monaghan P

http://www.w3.org/2001/XMLSchema#string

Powles TJ

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms

In situ intraduct carcinoma of the breast: a long term follow-up study.

Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

The neu oncogene encodes an epidermal growth factor receptor-related protein.

Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas.

P2888

P304

453-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1988.239

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

1988-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

20306223

http://www.w3.org/2001/XMLSchema#string

P698

2849975

http://www.w3.org/2001/XMLSchema#string

P932

2246778

http://www.w3.org/2001/XMLSchema#string